With Glax­o­SmithK­line in the rearview mir­ror, Ab­bas Hus­sain is ready to lead a biotech of his own; Doug Tre­co scores first CEO job since Ra Phar­ma buy­out

Ab­bas Hus­sain was once con­sid­ered to be a top can­di­date to take An­drew Wit­ty’s place as CEO of Glax­o­SmithK­line in 2016. When the job was ul­ti­mate­ly giv­en to Em­ma Walm­s­ley — who has been in her own spots of both­er re­cent­ly — Hus­sain quit as GSK’s glob­al pres­i­dent of phar­ma­ceu­ti­cals and vac­cines in Jan­u­ary 2017. Four years lat­er, Hus­sain gets be­hind the CEO wheel at Swiss-based Vi­for Phar­ma, which has a PDU­FA date of Aug. 23 with its Carapart­nered drug Ko­r­su­va for pru­ri­tis in he­modial­y­sis pa­tients. Hus­sain of­fi­cial­ly takes over for the de­part­ing Ste­fan Schulze a week be­fore that date on Aug. 16. Schulze had been in charge at Vi­for since March 2020 and is leav­ing for per­son­al rea­sons.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Principal

Alexandria Real Estate Equities

Cambridge, MA, USA